Literature DB >> 12817763

RANKL expression is related to the differentiation state of human osteoblasts.

Gerald J Atkins1, Panagiota Kostakis, Beiqing Pan, Amanda Farrugia, Stan Gronthos, Andreas Evdokiou, Kate Harrison, David M Findlay, Andrew C W Zannettino.   

Abstract

Human osteoblast phenotypes that support osteoclast differentiation and bone formation are not well characterized. Osteoblast differentiation markers were examined in relation to RANKL expression. RANKL expression was induced preferentially in immature cells. These results support an important link between diverse osteoblast functions. Cells of the osteoblast lineage support two apparently distinct functions: bone formation and promotion of osteoclast formation. The aim of this study was to examine the relationship between these phenotypes in human osteoblasts (NHBC), in terms of the pre-osteoblast marker, STRO-1, and the mature osteoblast marker, alkaline phosphatase (AP), and the expression of genes involved in osteoclast formation, RANKL and OPG. The osteotropic stimuli, 1alpha,25(OH)2vitamin D3 (vitD3) and dexamethasone, were found to have profound proliferative and phenotypic effects on NHBCs. VitD3 inhibited NHBC proliferation and increased the percentage of cells expressing STRO-1 over an extended culture period, implying that vitD3 promotes and maintains an immature osteogenic phenotype. Concomitantly, RANKL mRNA expression was upregulated and maintained in NHBC in response to vitD3. Dexamethasone progressively promoted the proliferation of AP-expressing cells, resulting in the overall maturation of the cultures. Dexamethasone had little effect on RANKL mRNA expression and downregulated OPG mRNA expression in a donor-dependent manner. Regression analysis showed that RANKL mRNA expression was associated negatively with the percentage of cells expressing AP (p < 0.01) in vitD3- and dexamethasone-treated NHBCs. In contrast, RANKL mRNA expression was associated positively with the percentage of STRO-1+ cells (p < 0.01). In NHBCs sorted by FACS based on STRO-1 expression (STRO-1bright and STRO-1dim populations), it was found that vitD3 upregulated the expression of RANKL mRNA preferentially in STRO-1bright cells. The results suggest that immature osteoblasts respond to osteotropic factors in a potentially pro-osteoclastogenic manner. Additionally, the dual roles of osteoblasts, in supporting osteoclastogenesis or forming bone, may be performed by the same lineage of cells at different stages of their maturation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12817763     DOI: 10.1359/jbmr.2003.18.6.1088

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  68 in total

1.  Pasteurella multocida toxin-stimulated osteoclast differentiation is B cell dependent.

Authors:  Dagmar Hildebrand; Klaus Heeg; Katharina F Kubatzky
Journal:  Infect Immun       Date:  2010-10-18       Impact factor: 3.441

2.  Targeting bone as a therapy for myeloma.

Authors:  Ping Wu; Gareth J Morgan
Journal:  Cancer Microenviron       Date:  2011-08-11

3.  Morphological features of osteoclasts derived from a co-culture system.

Authors:  Vanessa Nicolin; Giovanna Baldini; Renato Bareggi; Marina Zweyer; Giorgio Zauli; Mauro Vaccarezza; Paola Narducci
Journal:  J Mol Histol       Date:  2006-09-15       Impact factor: 2.611

4.  Mineralised collagen--an artificial, extracellular bone matrix--improves osteogenic differentiation of bone marrow stromal cells.

Authors:  Anne Bernhardt; Anja Lode; Sabine Boxberger; Wolfgang Pompe; Michael Gelinsky
Journal:  J Mater Sci Mater Med       Date:  2007-06-28       Impact factor: 3.896

5.  A physical mechanism for coupling bone resorption and formation in adult human bone.

Authors:  Thomas Levin Andersen; Teis Esben Sondergaard; Katarzyna Ewa Skorzynska; Frederik Dagnaes-Hansen; Trine Lindhardt Plesner; Ellen Margrethe Hauge; Torben Plesner; Jean-Marie Delaisse
Journal:  Am J Pathol       Date:  2008-12-18       Impact factor: 4.307

6.  Histopathological assessment of prostate cancer bone osteoblastic metastases.

Authors:  Martine P Roudier; Colm Morrissey; Lawrence D True; Celestia S Higano; Robert L Vessella; Susan M Ott
Journal:  J Urol       Date:  2008-07-18       Impact factor: 7.450

7.  Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism.

Authors:  Gerald J Atkins; Peter S Rowe; Hui P Lim; Katie J Welldon; Renee Ormsby; Asiri R Wijenayaka; Lesya Zelenchuk; Andreas Evdokiou; David M Findlay
Journal:  J Bone Miner Res       Date:  2011-07       Impact factor: 6.741

8.  RANKL cytokine enhances TNF-induced osteoclastogenesis independently of TNF receptor associated factor (TRAF) 6 by degrading TRAF3 in osteoclast precursors.

Authors:  Zhenqiang Yao; Wei Lei; Rong Duan; Yanyun Li; Lu Luo; Brendan F Boyce
Journal:  J Biol Chem       Date:  2017-04-24       Impact factor: 5.157

9.  Dlx5, a positive regulator of osteoblastogenesis, is essential for osteoblast-osteoclast coupling.

Authors:  Nadeem Samee; Valerie Geoffroy; Caroline Marty; Corinne Schiltz; Maxence Vieux-Rochas; Giovanni Levi; Marie-Christine de Vernejoul
Journal:  Am J Pathol       Date:  2008-07-31       Impact factor: 4.307

10.  Vitamin D metabolism and action in human bone marrow stromal cells.

Authors:  Shuanhu Zhou; Meryl S LeBoff; Julie Glowacki
Journal:  Endocrinology       Date:  2009-12-04       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.